However, none of the genetic proxies for lipid-lowering drugs (PCSK9 and NPC1L1) targets were found to be causally associated with the risk of cystic kidney disease (Figure 2 and Figure S1). This evidence concerns the gene NPC1L1 and cystic kidney disease.